Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

255P - MEX3A is a prognostic biomarker and correlates with RNA splicing and cell proliferation in endometrial cancer by analysis of RNA-seq data

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Endometrial Cancer

Presenters

Huining Jing

Citation

Annals of Oncology (2019) 30 (suppl_9): ix77-ix90. 10.1093/annonc/mdz426

Authors

H. Jing

Author affiliations

  • Department Of Obstetrics And Gynecology, West China Medical Center of Sichuan University, 610041 - Chengdu/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 255P

Background

MEX3A is an evolutionarily conserved RNA-binding protein (RBP), of which functions and target genes in mammals remain largely unknown. Also, no previous study has shown the role of MEX3A in endometrial cancer.

Methods

We screened the differentially expressed genes (DEGs) and miRNAs (DEmiRs) between endometrial cancer samples and paired adjacent noncancerous endometrium samples with RNA-seq data. Then, we used package clusterProfiler to profile the GO and KEGG enrichment analysis of the most highly correlated genes with MEX3A, as well as the overlap genes with up-regulated DEGs. We evaluated the prognostic effect of genes using the Kaplan-Meier Plotter database. MEX3A tissue-specific expression was analyzed via the Human Protein Atlas database and TIMER. Methylation analysis was generated by MethHC and Wanderer.

Results

The volcano plot of DEmiRs showed a significant reduction in tumor suppressor miR-139 in tumor tissues compared to normal tissues. We totally identified 422 target genes of miR-139-5p using the prediction software TargetScan (7.1 version). MEX3A was one of the seven overlapping genes that we got between the miRNA target genes and the 842 up-regulated DEGs. MEX3A was significantly overexpressed in many types of tumor tissues, and interestingly, it had the highest expression in the female tissues. In addition, high MEX3A expression was significantly correlated with poor OS and progression-free survival (PFS) in endometrial cancers (OS HR = 2.07, P = 0.0021; PFS HR = 2.11, P = 0.0047). The GO analysis of top 5% most highly correlated genes with MEX3A in endometrial cancer revealed that biology processes associated with RNA splicing were mainly enriched. Simultaneously, the most enriched pathway was spliceosome, which indicated that the RBP may play an important role in the RNA splicing. Meanwhile, the MEX3A promoter region in the tumor tissue was hypomethylated compared to normal tissue. In addition, the MEX3A promotor differential methylation level is negatively correlated with MEX3A mRNA expression (corr = -0.512).

Conclusions

These findings suggest MEX3A is a potential prognostic biomarker in endometrial cancer and might play an oncogenic role as a novel cancer-critical splicing factor.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.